Abstract: The present invention concerns novel polypeptides having opioid receptor activity, the genetic material permitting their expression, recombinant cells expressing these polypeptides, and their use.
Abstract: The present invention concerns novel polypeptides having opioid receptor activity, the genetic material permitting their expression, recombinant cells expressing these polypeptides, and their use.
Abstract: The present invention concerns novel polypeptides having opioid receptor activity, the genetic material permitting their expression, recombinant cells expressing these polypeptides, and their use.
Abstract: Compounds of general formula (I)
are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.
Type:
Grant
Filed:
March 5, 1998
Date of Patent:
February 13, 2001
Assignee:
Astra Pharma Inc.
Inventors:
Daniel Delorme, Edward Roberts, Zhongyong Wei
Abstract: Compounds of general formula (I) ##STR1## wherein m is 0 or 1, and n is 1 or 2; are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.
Abstract: Compounds of the formula (I) ##STR1## as well as their pharmaceutically acceptable salts, and pharmaceutical compositions comprising the novel compounds. The novel compounds of the formula (I) are useful in the management of pain.
Type:
Grant
Filed:
April 24, 1997
Date of Patent:
October 10, 2000
Assignee:
Astra Pharma Inc.
Inventors:
Edward Roberts, Niklas Plobeck, Claes Wahlestedt